Newtyn Management LLC Lowers Stock Holdings in Galapagos NV (NASDAQ:GLPG)

Newtyn Management LLC lowered its stake in shares of Galapagos NV (NASDAQ:GLPG - Free Report) by 46.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 270,000 shares of the biotechnology company's stock after selling 230,000 shares during the period. Galapagos accounts for 1.3% of Newtyn Management LLC's investment portfolio, making the stock its 23rd largest position. Newtyn Management LLC owned 0.41% of Galapagos worth $7,425,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. R Squared Ltd purchased a new stake in Galapagos in the fourth quarter valued at $26,000. BNP Paribas Financial Markets raised its position in Galapagos by 45.9% in the fourth quarter. BNP Paribas Financial Markets now owns 8,972 shares of the biotechnology company's stock valued at $247,000 after purchasing an additional 2,824 shares during the period. QRG Capital Management Inc. raised its position in Galapagos by 21.7% in the fourth quarter. QRG Capital Management Inc. now owns 10,455 shares of the biotechnology company's stock valued at $288,000 after purchasing an additional 1,866 shares during the period. XTX Topco Ltd raised its holdings in shares of Galapagos by 137.8% in the 4th quarter. XTX Topco Ltd now owns 19,833 shares of the biotechnology company's stock valued at $545,000 after buying an additional 11,492 shares during the period. Finally, Bank of America Corp DE grew its position in Galapagos by 19.6% in the 4th quarter. Bank of America Corp DE now owns 22,454 shares of the biotechnology company's stock valued at $617,000 after acquiring an additional 3,684 shares in the last quarter. Institutional investors and hedge funds own 32.46% of the company's stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the company. StockNews.com cut Galapagos from a "hold" rating to a "sell" rating in a research report on Friday, April 25th. Barclays reissued an "underweight" rating on shares of Galapagos in a research report on Thursday, January 23rd. Finally, Morgan Stanley cut Galapagos from an "equal weight" rating to an "underweight" rating and decreased their price objective for the stock from $31.00 to $22.00 in a research report on Friday, February 14th. Five equities research analysts have rated the stock with a sell rating and four have given a hold rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Reduce" and a consensus target price of $25.33.

Galapagos Stock Performance

Galapagos stock traded down $0.05 during mid-day trading on Monday, hitting $27.71. 130,096 shares of the company were exchanged, compared to its average volume of 233,632. The business's 50 day simple moving average is $25.46 and its two-hundred day simple moving average is $25.86. Galapagos NV has a 12-month low of $22.36 and a 12-month high of $31.23.

Galapagos (NASDAQ:GLPG - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The biotechnology company reported ($2.47) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($2.24). The business had revenue of $97.33 million during the quarter, compared to the consensus estimate of $72.22 million. On average, analysts anticipate that Galapagos NV will post -1.6 EPS for the current fiscal year.

About Galapagos

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.